Overview

CTI provides this data for informational and research purposes only. The data is not intended for trading purposes. Neither CTI nor any of its data content providers shall be liable for any errors or delays in the content, or for any actions in reliance thereon. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

Please see Terms of Use for this website.

Investor Relations Contacts
USEU
Monique Greer
+1 206-272-4343
Laura Villa
+39 02 89659706
Ed Bell
+1 206-272-4345
Elena Bellacicca
+39 02 89659700
Recent News
DateTitle 
May 20, 2013German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)Printer Friendly Version
May 15, 2013Cell Therapeutics to Present at Upcoming Investor ConferencesPrinter Friendly Version
May 02, 2013Cell Therapeutics Reports First Quarter 2013 Financial ResultsPrinter Friendly Version
Apr 24, 2013Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013Printer Friendly Version
Apr 10, 2013Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI® (pixantrone)Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue